Membership Get unlimited access
Razor is a communications consultancy,
We build and protect the reputation of your organisation, service or brand, with a team of high calibre people who care about doing a great job for our clients.
As well as offering comprehensive, strategic public relations and communications services to a wide range of national and multinational companies across Europe, we are increasingly recognised as leaders in the field of issues, risk and crisis communication management, particularly in the food, health and chemical industries. More on what we do
We believe in a business-focused approach to communications, an approach that creates powerful, incisive programmes that deliver measurable results.More on how we work
Numerous of the finest stocks to buy come with a high price tag. This truth is hardly unexpected: Business with exciting growth potential customers will generally attract a lot of attention, and as financiers load up on shares of these business, their stock rates rise accordingly.
Charlotte’s Web Holdings
Charlotte’s Web supplies cannabidiol (CBD)- obtained items such as gummies and oils, and the company stands as one of the leading players in this market. Charlotte’s Web continues to broaden its footprint in this market, too. The business’s products can now be discovered in more than 10,000 stores throughout the U.S., and that number is set to increase soon: Charlotte’s Web recently revealed it would obtain Abacus Health, which provides non-prescription CBD items in more than 12,000 shops, in an all-stock transaction valued at $69 million.
Image source: Getty Images.
This transaction, which is anticipated to close at some point this year, will considerably increase Charlotte’s Web’s footprint in its market and diversify the business’s item offering. Still, critics might indicate a significant challenge that might impede Charlotte’s Web’s development: Last year, the U.S. Food and Drug Administration (FDA) famously notified consumers about the dangers of CBD, cautioning that the compound can trigger liver damage.
The FDA has actually likewise provided alerting letters to numerous companies making unverified claims about the health benefits of their CBD-based items. These advancements did impact Charlotte’s Web’s financial performance; CEO Deanie Elsner kept in mind that “in November, the FDA issued a number of warning letters to particular CBD companies which triggered our clients to pull back throughout all channels, adversely impacting the sector and our sales.”
There is at least one other way in which the FDA is showing to be a thorn in Charlotte’s Web’s side. The company argues that its development is being hindered by the absence of regulatory direction relating to CBD items. Even with these challenges, I believe financiers would do well to wager on Charlotte’s Web. Not only will the current acquisition of Abacus Health boost its earnings and revenues, however in the long run, the company is prepared to profit once the FDA lastly does release these regulative directions.
To price estimate Elsner once again: “The chance for Charlotte’s Web will be both the growth of our circulation breadth across nationwide sellers, in addition to the expansion of our portfolio depth within each retailer. The catalyst for this significant income inflection point would be the FDA setting guidelines for dietary supplements.”
In my view, these aspects make Charlotte’s Web’s stock a buy, specifically thinking about that its shares are trading for just under $7 each at the moment.
Planet 13 Holdings
Planet 13 Holdings is a marijuana dispensary operator headquartered in Las Vegas. This isn’t simply any weed store: World 13 has managed to distinguish itself from its operators and carve out a specific niche for itself with its flagship area in Las Vegas, which it calls a “cannabis entertainment complex.” Put simply, the focus of this particular dispensary is on the experience of the consumers as much as on the marijuana items the company offers.
Planet 13′ “Warehouse store” boasts a restaurant and a coffee shop, amongst other things.
The business had more than a million visitors during the year, representing about 9%of cannabis sales in a competitive market in Nevada. Last year, while lots of cannabis companies were busy shedding much of their worth, Planet 13 Holdings’ stock soared by nearly 80%. Sure, the company isn’t doing almost also this year, but that’s hardly unexpected provided the existing market conditions. Looking forward, however, Planet 13 Holdings could be a huge winner in the long run.
The company has strategies to expand its presence and open eight more marijuana warehouse stores in several prominent U.S. cities over the next five years. Planet 13 Holdings is still in the early stages of its development, and as the business expands its presence, its earnings and earnings could follow suit.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Planet 13 Holdings Inc. The Motley Fool recommends Charlotte’s Web. The Motley Fool has a disclosure policy.”>
Prosper Junior Bakiny has no
position in any of the stocks pointed out.
The Motley Fool owns shares of and recommends Planet13 Holdings Inc.
The Motley Fool advises Charlotte’s Web.
The Motley Fool has a disclosure policy“>
Therabody will continue to embody Theragun’s initial mission and dedication of leading the tech health area by developing advanced items using exclusive innovation to provide natural health options for everybody. In addition to the Therabody rebrand, the company is releasing a proprietary USDA certified natural CBD line, TheraOne this summer as well as Theragun’s Fourth generation percussive massage gadgets with the intro of the brand’s brand-new exclusive motor utilizing QuietForce Innovation and Smart Percussive Therapy, effortlessly integrating with the updated Therabody app.
The brand-new product launches and combinations has actually resulted in a natural development for the company to evolve into its brand-new name. “Since the day I created Theragun to assist me with the pain caused by a bike accident, our objective as a business has been to assist others with their muscle tension and pain, whether it’s for an injury, a disorder or working out,” said Dr. Jason Wersland, Founder and Chief Health Officer of Therabody. ” We desire our customers to know under particular circumstances there are options to taking discomfort medication and Theragun has actually been among them. Now, with the launch of TheraOne, we are able to offer our consumers another natural health option that is not just reliable on its own, but likewise complements our Theragun Percussive Therapy gadgets. I’m delighted with this turning point of introducing Therabody and how it allows us to help more people. We are simply getting started as we continue to develop items backed by science that can further assist people feel better, naturally.”
Therabody’s goal is to develop product or services that educate and empower consumers to be in control of their own health. While the brand name will continue to champion availability and inclusivity through the products, services, and research study that Therabody has to offer, it will also offer more services that are both natural and efficient, additional assisting the neighborhood. Theragun and TheraOne are the two current departments under the new Therabody with strategies to establish and broaden into additional sectors in the future.
As far as rebranding during a pandemic, they did a face a couple of challenges and even needed to delay numerous of their launches. “Our initial launch date was just as COVID-19 started to strike the United States hard. Offered the timing, and our authentic commitment to health and wellness, we made the difficult choice to postpone the launch of our brand-new items,” shared CEO Benjamin Nazarian. “However, we have actually had the chance during this difficult time to contribute Theragun to medical facilities around the world and see the effect Theragun has been having on our frontline employees. We’ve also concentrated on giving back to those in need, contributing 250,000 meals to Feeding America.”
Nazarian and the group felt it was the right time to reveal the rebranding this previous week as more people have actually ended up being more accustomed to life in your home. Coronavirus has also affected Therabody to go back toddler beneficiary roots. “Due to the modification in the retail environment, we have highlighted our e-commerce channel, which is how we started as a business. We are excited to launch our new product line and share the next chapter in our story with our neighborhood as the stay at home policies are slowly starting to come to an end throughout the nation,” Nazarian continued. TheraOne is s lated to introduce in summer2020 With more than 2 years of dedicated research study and development prior to its launch, the TheraOne portfolio will consist of five brand-new proprietary full- spectrum CBD items that are all-natural and toxic substance totally free. The 5 new products were likewise formulated utilizing patent-pending Biosorb ™ technology to optimize the absorption of all the natural advantages the plant has to offer.
‘There Is An Active Discussion Of CBD Happening Across The Country,’ Says A New Report. And That Spells Opportunity.
In 2017, when celebrity host (The View) Whoopi Goldberg was enjoying the high point of her then-new CBD brand, Maya & Whoopi, a reporter asked what the next step was. “World domination,” Goldberg joked at the time.
She might have been onto something.
Goldberg this year parted ways with her business partner, Maya Elisabeth; the result was that their company folded. But if Goldberg back in 2017 was predicting a big future for CBD startups, she wasn’t off the mark, judging from a the findings of a new survey from New Frontier Data.
“The newness of the CBD experience for most consumers suggests there remains significant opportunity for well-developed brands to attract consumer attention and capture market share from existing market leaders,” the report says. A big reason why startups might have an edge, the researchers imply? The novelty factor.
“Consumers have not been using the products with sufficient longevity to create durable brand loyalty that is difficult to dislodge,” the report says.
To compile the study, New Frontier Data surveyed 4,074 U.S. adults in mid-March. The survey population consisted of 26% of subjects who earned less than $30,000; 27% earning $39,000 to $59,999; 27% earning $60,000 to $89,999; and 16% earning $90,000 and up.
Among the report’s chief takeaways:
Familiarity with CBD is an important factor
· CBD is hardly unknown to the American mainstream. “Nearly 9 in 10 Americans are familiar with CBD,” the report says. Some 86% of those surveyed had heard of CBD, and a majority (55%) were interested in learning more. Younger cohorts tended to be more interested than older groups.
· Word of mouth is a common thread: Nearly 3 in 4 (73%) of those surveyed who’d heard of CBD reported having had a conversation about it, including the 67% who had not consumed it. People reported that their conversations were largely positive.
· Positive associations: 51% of those surveyed knew a friend or family member who’d used CBD, and nearly 1 in 5 (17%) had recommended CBD to someone else.
· Frequency: Among Americans who reported ever having consumed CBD, 40% said they did so at least once a week, with older consumers using it more frequently than younger ones.
· CBD consumers seem to be evangelists. A majority, 56%, said they had recommended CBD products to someone else.
Stress and pain are major reasons for use
· Three in five (60%) of consumers surveyed reported using CBD in a context that might be called “unwinding,” such as relaxation, relief of stress or anxiety reduction. The primary use, however (41%), was pain management.
Means of Consumption
· Oils and tinctures led the way, at 38% (of the ways in which consumers surveyed consume CBDs). Topicals were the next most widely used method, at 19%; then: food or drinks, 18%; flower, 8%; pills/capsules, 7%; and vaping, 7%.
· Some 43% of consumers said they used less than 30 mg. a day; 22% reported using 50 mg. or more; and 12% used 100 mg. or more a day.
· Some 65% of consumers surveyed said CBD had positively affected their quality of life. Only 2% described a negative effect.
Level of expenditure
· Most consumers (59%) said they spent less than $50 a month on CBD.
· Some 46% of male consumers surveyed said they used CBD at least once a week, versus 36% of women in the survey population.
· On average, men spent more for CBD than did women. Men were more likely (21%) than women (12%) to spend more than $100 per month. Purchasers ages 35 to 54 were the most likely (21%) of any group to spend more than $100 per month.
· CBD purchasers reported being generally happy with the products they were able to purchase, depending on the regulations in their geographic area; 71% agreed they were satisfied with their purchases.
· When selecting which CBD product to purchase, price and quantity of CBD were the most important factors to those surveyed. Convenience of location and service from staff were also important criteria.
· Some 51% of purchasers said they usually purchased familiar brands. About 29% said they would be likely to purchase CBD in the next six months.
Where the Opportunities Lie
For CBD startups, the women’s market for might be one smart place to focus, considering that male survey respondents were far more likely (21%) than women (12%) to spend more than $100 per month.
Another wise move might be to market only products backed by clinical studies and clear, authoritative information. The reasons here would be the importance consumers put on reliable information, as well as the strict FDA restrictions against promoting CBD for medical purposes.
Infusions as a method for consumption also seem to be of growing interest, while smoking is losing users due to social norms, especially during the current COVID-19 crisis when so many cannabis medical users are housebound.
Finally, given the anxiety during the crisis and the prevalence of word of mouth in spreading information about CBDs, companies might want to turn to such marketing channels as referral discounts, loyalty programs and high-production-value consumer testimonials, according to the New Frontier Data report.
In recent weeks, Aurora Cannabis ( NYSE: ACB) stock has seen new life. It all began with the business launching its third-quarter 2020 results on May 14, which revealed 18%revenue development from the prior period. A dedication to more improving its costs likewise provided financiers a factor to be hopeful that success may not be simply a pipe dream.
Then, on May 20, the marijuana producer also announced it was acquiring Reliva, a cannabidiol (CBD) brand name that would allow it to penetrate the U.S. market. As amazing an opportunity as that might seem initially look, here’s why investors shouldn’t put excessive stock in it.
It’s entering an already crowded hemp market
Many headlines advertise Aurora’s recent acquisition as the company getting into the U.S. CBD market. All types of CBD aren’t legal in the U.S. (federally), and Aurora can’t provide non-hemp items that include more than 0.3%of tetrahydrocannabinol (THC).
Image source: Getty Images.
The excellent news is that according to research companies BDS Analytics and Arcview Market Research, the overall CBD market in the U.S. is still expected to reach $20 billion by 2024, up from simply $1.9 billion in2018 And the bad news is that the rosy outlook for CBD does not suggest the opportunity is going to equate into considerable growth for Aurora.
That’s since Aurora will not just be competing with other U.S. companies for market share, but with Canadian pot stocks that are also looking to benefit from the opportunities in the hemp market. The business’s essential rival, Canopy Development ( NYSE: CGC) is already in the CBD hemp market in the U.S., and one of the relocations it’s making to cut expenses is to really stop farming for hemp at its Springfield, New York location. The pot giant stated it had “an abundance of hemp produced in the 2019 growing season” that it was going to offer initially prior to making more. It’s not just Canopy Development that has an excess of supply, either; it’s a problem for the whole industry.
Julie Lerner, who is CEO of the PanXchange where hemp is traded, confirmed in January that there was much more supply than demand for hemp. That’s not going to bode well for a business like Aurora, which is trying to enhance on its margins and get closer to profitability.
Having access to thousands of places doesn’t guarantee growth
In the news release revealing the acquisition of Reliva, there wasn’t a whole lot of information on how huge of a gamer the business is in the hemp market. Aurora referred to Reliva as “a leader in the sale of hemp-derived CBD items in the United States,” there wasn’t anything to quantify or justify that other than to say that its items were sold in more than 20,000 U.S. areas.
Hemp-derived CBD business Charlotte’s Web ( OTC: CWBHF), offers its products in fewer areas, and it has far stronger sales. In the company’s first-quarter results, launched on May 14, Charlotte’s Web revealed that its reach exceeded 11,000 areas which its sales for the three-month period totaled $215 million. And although it’s seen an increase in the number of shops carrying its products, that hasn’t equated into substantial growth.
A year back, the company tape-recorded sales of $217 million when its products were in more than 6,000 locations. The increase in locations over the previous year hasn’t resulted in a surge in sales for Charlotte’s Web, and Aurora investors shouldn’t make the error of presuming more areas indicate greater earnings.
The move doesn’t make Aurora a much better buy
Aurora expects Reliva to assist the Alberta-based pot manufacturer inch closer to achieving a favorable adjusted earnings before income, taxes, depreciation, and amortization (EBITDA) figure. With Aurora sustaining an adjusted EBITDA loss of 50.9 million Canadian dollars in Q3, it has a long method to go to reach breakeven, with or without Reliva. The acquisition may help play a small part in improving Aurora’s bottom line, but the company still has a lot of work to do in enhancing its financials.
The only certainty, it appears, is that the deal will lead to more dilution for shareholders. The business expect the offer will close in June, and it will cost Aurora as much as $45 million in shares.
The acquisition is a modest one for Aurora that will help contribute to its top line, however that’s about it; Aurora remains a dangerous buy, and one quarter and one acquisition isn’t going to change that. The pot stock is still down more than 80%over the past 12 months, notably even worse than the Horizons Cannabis Life Sciences ETF ( OTC: HMLSF), which has actually fallen by 60%.